BMC Musculoskeletal Disorders · 2014 · 33 citations · 10 references
PharmacyInternal MedicinePharmacotherapyHypersensitivityPharmacovigilanceRheumatologyAdverse Drug Event DetectionAdverse Drug Event PreventionAdverse Drug Event ReportingImmune-related Adverse EventsImmunotherapy SafetyRheumatoid ArthritisInadequate TreatmentInfusion Rate EffectsInfusion SafetyInfusion-related Adverse ReactionsInfusion-related ReactionsRheumatoid Arthritis PharmacotherapyRheumatoid Arthritis TherapyRituximab-based Therapy
BACKGROUND: As recommended in the current prescribing information, rituximab infusions in patients with rheumatoid arthritis (RA) take 4.25 hours for the first infusion and 3.25 hours for subsequent infusions, which is a burden on patients and the health care system. We therefore evaluated the safety of infusing rituximab at a faster rate for an infusion period of 2 hours in patients with RA. METHODS: Patients with an inadequate response to anti-TNF who were rituximab-naive or -experienced received 2 courses of rituximab: Infusion 1 (Day 1) was administered over the standard 4.25 hours, and Infusions 2 (Day 15), 3 (Day 168) and 4 (Day 182) were administered over a faster 2-hour period. The primary endpoint was incidence of infusion-related reactions (IRRs) associated with Infusion 2. RESULTS: Of the 351 patients enrolled, 87% and 13% were rituximab-naive and -experienced, respectively. The incidence (95% CI) of IRRs associated with Infusion 1 was 16.2% (12.5%, 20.5%) and consistent with weighted historical incidence of 20.7% (19.4%, 22.1%). The incidence (95% CI) of IRRs associated with Infusions 2, 3, and 4 compared with respective weighted historical incidences at the standard infusion rate was 6.5% (4.1%, 9.7%) vs 8.1% (7.2%, 9.1%); 5.9% (3.5%, 9.3%) vs 11.5% (10.3%, 12.8%); and 0.7 (0.1%, 2.6%) vs 5.0% (4.2%, 6.0%), respectively. All IRRs were grade 1 or 2, except for 3 grade 3 IRRs associated with Infusion 1 and 2 grade 3 IRRs associated with Infusion 2. Four patients experienced a total of 5 grade 3 IRRs; 3 of these patients continued on to received subsequent infusions at the faster rate. There were no serious IRRs. CONCLUSION: This study demonstrated that rituximab can be administered at the faster infusion rate at the second and subsequent infusions without increasing the rate or severity of IRRs.
10
Stanley Cohen, Paul Emery, Maria Greenwald et al. · Arthritis & Rheumatism · 2006 · 1.6K citations
Ronald van Vollenhoven, Paul Emery, Clifton O. Bingham et al. · Annals of the Rheumatic Diseases · 2012 · 391 citations · Full text
P. Emery, Atul Deodhar, William F. C. Rigby et al. · Annals of the Rheumatic Diseases · 2010 · 347 citations · Full text
Edward Keystone, Paul Emery, Charles Peterfy et al. · Annals of the Rheumatic Diseases · 2008 · 240 citations · Full text
Philip J. Mease, Stanley Cohen, Norman Gaylis et al. · The Journal of Rheumatology · 2010 · 124 citations